In vivo evaluation of a pro-healing polydopamine coated stent through an in-stent restenosis rat model

2021 ◽  
Vol 9 (1) ◽  
pp. 212-220
Author(s):  
Adrien Hertault ◽  
Feng Chai ◽  
Mickael Maton ◽  
Jonathan Sobocinski ◽  
Patrice Woisel ◽  
...  
Keyword(s):  
Rat Model ◽  
Drug Eluting Stents ◽  
In Vivo Evaluation ◽  
Acute Thrombosis ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

Drug-eluting stents have demonstrated efficiency in in-stent restenosis (ISR) but induced a risk of late acute thrombosis by delaying strut re-endothelialization.

scholarly journals In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario

2019 ◽  
Vol 71 (1) ◽  
Author(s):  
Ganesh Paramasivam ◽  
Tom Devasia ◽  
Shabeer Ubaid ◽  
Ashwitha Shetty ◽  
Krishnananda Nayak ◽  
...  
Keyword(s):  
Real World ◽  
Clinical Presentation ◽  
Drug Eluting Stents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

scholarly journals Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Wen-Juan Xiu ◽  
Hai-Tao Yang ◽  
Ying-Ying Zheng ◽  
Yi-Tong Ma ◽  
Xiang Xie
Keyword(s):  
Observational Studies ◽  
Second Generation ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Randomized Controlled ◽  
Stent Restenosis ◽  
Significant Difference ◽  
Drug Eluting ◽  
In Stent Restenosis

Background. In-stent restenosis (ISR) remains a common problem following percutaneous coronary intervention (PCI). However, the best treatment strategy remains uncertain. There is some controversy over the efficacy of drug-eluting balloons (DEBs) and second-generation drug-eluting stents (DESs) for treating ISR. Methods. A meta-analysis was used to compare the efficacy of the DEB and second-generation DES in the treatment of ISR. The primary endpoint is the incidence of target lesion revascularization (TLR). The secondary endpoint is the occurrence of target vessel revascularization (TVR), myocardial infarction (MI), all-cause death (ACM), cardiac death (CD), major adverse cardiac events (MACEs), minimum luminal diameter (MLD), late luminal loss (LLL), binary restenosis (BR), and percent diameter stenosis (DS%). Results. A total of 12 studies (4 randomized controlled trials and 8 observational studies) including 2020 patients with a follow-up of 6–25 months were included in the present study. There was a significant difference in the MLD between the two groups during follow-up (P=0.007, RR = 0.23, and 95% CI: 0.06–0.4 mm). There was no significant difference in LLL, BR, or DS% and the overall incidence of MACEs between the two groups. Subgroup analysis showed no significant difference in the incidence of primary and secondary endpoints when considering RCTs or observational studies only. Conclusions. The efficacy of the DEB and second-generation DES in the treatment of ISR is comparable. However, our results need further verification through multicenter randomized controlled trials.

In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients

2018 ◽  
Vol 71 (11) ◽  
pp. 917-925
Author(s):  
Héctor Cubero-Gallego ◽  
Rafael Romaguera ◽  
Josep Gómez-Lara ◽  
Joan A. Gómez-Hospital ◽  
Manel Sabaté ◽  
...  
Keyword(s):  
Mtor Inhibitors ◽  
Drug Eluting Stents ◽  
Diabetic Patients ◽  
Synergic Effect ◽  
In Vivo Evaluation ◽  
Drug Eluting

In-stent restenosis in the drug-eluting stent era

2018 ◽  
pp. 453-472
Author(s):  
Jaya Chandrasekhar ◽  
Adriano Caixeta ◽  
Philippe Généreux ◽  
George Dangas ◽  
Roxana Mehran
Keyword(s):  
Low Frequency ◽  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Metal Stents ◽  
Pharmacological Agents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

Since the inception of percutaneous coronary intervention, restenosis has been considered a significant problem. Although drug-eluting stents (DES) have reduced rates of in-stent restenosis (ISR) compared with bare metal stents across all lesion subsets, ISR has not been abolished. DES efficacy has been limited by suboptimal polymer biocompatibility, efficacy of pharmacological agents, in vivo pharmacokinetic properties, and local drug resistance and toxicity. While the first two DES to be manufactured (sirolimus- and paclitaxel-eluting stents) have the longest clinical follow-up, extensive data are now also available on zotarolimus- and everolimus-eluting stents. The uptake of biolimus-eluting stents has recently increased in clinical practice. Although the low frequency of DES ISR makes it difficult to investigate this condition fully, many studies have examined the mechanism, incidence, predictors, and optimal treatment of DES restenosis. This review discusses the data relevant to DES restenosis and the perspective on the current treatment of this condition.

scholarly journals Predictive value of the CHA2DS2-VASc Score in detecting in-stent restenosis among patients who underwent previous revascularization due to stable angina or acute coronary syndromes

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
R Ayman ◽  
H Shehata ◽  
E AL-Fikki ◽  
Y Gomaa
Keyword(s):  
Significant Relationship ◽  
Stable Angina ◽  
Predictive Value ◽  
Long Term Results ◽  
Drug Eluting Stents ◽  
P Value ◽  
Stent Restenosis ◽  
Stent Length ◽  
Drug Eluting ◽  
In Stent Restenosis

Abstract Background Introduction of coronary stents in the field of interventional cardiology has significantly improved short- and long-term results of the percutaneous coronary interventions but in the same time they became responsible for development of a new entity called neo-intimal hyperplasia (NIH). If overexpressed, NIH can lead to so-called in-stent restenosis (ISR). Objective To assess the predictive value of the CHA2DS2-VASc Score in detecting in-stent restenosis among patients who underwent previous revascularization in Proximal Left Anterior Descending(LAD) Artery using Drug Eluting Stents (DES) due to stable angina and acute coronary syndrome. Material and Methods This study was conducted over 113 pateints to assess the predictive value of the CHA2DS2-VASc Score in detecting in-stent restenosis among patients who underwent previous revascularization in Proximal Left Anterior Descending (LAD) Artery using Drug Eluting Stents (DES). Results From the study population collected(n = 113), 18.4% of which were females (n = 21), statistically significant relation was found between DES-ISR and CHADSVasc score (p value =0.033). A significant relationship existed between ISR and CHADVasc score 3 or more, and each of: Age(p value= 0.022), DM(p value=0.029), SBP during the procedure(p value = 0.036), time since the PCI was done(p value =0.001), stent length(p value=0.028), pattern of the lesion and management of the lesions as individual variables (p value less than0.001). However, non-significant relationship could be concluded between ISR and each of gender(p value= 0.987), CHF(p value=0.163), HTN(p value=0.446), vascular diseases (p value=0.662), CAD type (SCAD or ACS)(p value=0.616), DBP during the procedure(p value=0.167), creatinine clearance (p value=0.69), HBA1c(p value=0.091), use of DAPT(p value=0.198), the duration of DAPT use(p value=0.873), type of P2Y12 inhibitor used(p value=0.083), use of statins(p value=0.402), beta blockers or nitrates (p values= 1 & 0.836, respectively) and stent diameter used (p value=0.615) Conclusion This study was able to show a significant relationship between ISR and each of CHADVasc score, Age, DM, SBP during the procedure, time since the PCI was done, stent length used, pattern of the lesion and management of the lesions

scholarly journals Role of pre-procedural laboratory parameters in predicting in stent restenosis of drug eluting stents

2018 ◽  
Vol 70 ◽  
pp. S42
Author(s):  
Zeeshan Ahmed Mumtaz ◽  
Avinash Ashok Guthe ◽  
Milind Phadke ◽  
Zohaib Shaikh ◽  
Ajay Umakant Mahajan ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Laboratory Parameters ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

scholarly journals TCT-705 Current treatment strategies for in-stent restenosis in the era of drug eluting stents: A Meta-analysis

2018 ◽  
Vol 72 (13) ◽  
pp. B282
Author(s):  
Haroon Kamran ◽  
Kleanthis Theodoropoulos ◽  
Carla Saladini ◽  
Jonathan Marmur ◽  
Giulio Stefanini
Keyword(s):  
Meta Analysis ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Drug Eluting Stents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis
Sign in / Sign up

Export Citation Format

Share Document